Based on the favorable policies of the pilot implementation of marketing authorization holder (MAH) system, the Company, combined with its own advantages, is committed to reaching strategic cooperation with the various pharmaceutical companies in the cooperative R&D and cooperative production of soft capsule preparations so as to facilitate the smooth approval of generic drugs, improved new drugs, new drugs, etc. in the Sino-U.S. markets.
1. Provide one-stop service from R&D to production;
2. Realize the simultaneous application both in
3. Be familiar with Sino-U.S. laws and regulations and application paths, avoid intermediate experiment links, and speed up listing of the products.